2021 | 2020 | 2019 | 2018

April 29, 2021

Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients

- Independent data safety monitoring board (DSMB) formally recommends investigational combination therapy advance to Phase 3 following Phase 2 pre-specified analysis for safety and efficacy
- Currently enrolling Phase 3 study enables expansion into a broad range of international trial sites


April 21, 2021

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

- New combination trial of an RNA-targeted therapeutic candidate and an HBV immunotherapeutic candidate aimed at delivering a functional cure for chronic hepatitis B infection


23 March 2021

Brii Biosciences Closes US$155 Million Series C Financing

- Financing led by Invesco Developing Markets Fund, joined by a syndicate of new and current investors
- Proceeds will support accelerating clinical development programs in the United States and China


3 March 2021

Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients

- The complete dataset from this study is evolving, including important sensitivity and sub-group analysis, which will help inform whether a treatment benefit can be observed in particular subgroups of hospitalized patients.
- Additional studies of the BRII-196 and BRII-198 combination are ongoing in ambulatory COVID-19 patients through ACTIV-2 clinical trial in collaboration with NIH-NIAID.



17 December 2020

Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities

- Initiated clinical research of investigational monoclonal antibodies BRII-196 and BRII-198 in combination for the treatment of COVID-19 in collaboration with the NIH-NIAID
- Continues to rapidly advance the development of potential therapeutics for the mitigation of serious infectious disease threats by HBV, multi-drug resistant gram-negative bacteria, and HIV
- Continues to advance CNS programs with IND for BRII-296 planned for January 2021
- Expanded U.S. Leadership Team with Executive Appointments


September 18 2020

Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions

- Rogers Yongqing Luo, B.M., MBA, President of Brii Bio and General Manager for Greater China, will lead acceleration of Brii Bio’s China strategy and expand the company’s capabilities in access and partnerships
- Ankang Li, Ph.D., J.D., CFA, Brii Bio’s Chief Financial Officer, will lead all financial and corporate development functions


Mar 31, 2020

Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19

- Multiple highly potent, neutralizing antibodies already identified from convalesced patients
- First-in-human trials planned for third quarter this year


Mar 11, 2020

Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses

- Brii Biosciences will provide funding and expertise in infectious disease treatment modalities for projects in development in Aaron Diamond AIDS Research Center and other Columbia Laboratories –


Dec 03, 2019

Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.

- Dr. Kraus to lead newly-created Neurosciences Therapy Area
- Zhijian Chen, Ph.D., named Strategic Scientific Advisor


Nov 21, 2019

Brii Biosciences Expands Infectious Disease Pipeline

- Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases
- Company pipeline now includes up to 12 partnered assets, in addition to internal development programs
- Infectious disease focus will address disproportional unmet need in China and support global public health


Nov 14, 2019

VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

- Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection
- Two-part, dose-escalation study expected to enroll up to 65 patients
- Initial data expected in H2 2020


Dec 11, 2018

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today a strategic collaboration with Brii Biosciences…


Dec 06, 2018

Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients

Brii Biosciences, a company committed to serving patients’ needs and improving public health in China, today announced several research collaborations that significantly advance its efforts to develop innovative medicines to meet the unique needs of patients in China.


Oct 02, 2018

FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018

Beijing, China – October 2, 2018 – Brii Biosciences today was named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.


May 24, 2018

Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients

Brii Bio aims to accelerate the development and delivery of breakthrough medicines in China through partnerships, best-in-class research and development, and the disruptive application of digital and data insight.